Please use this identifier to cite or link to this item:
|Title:||Clinical and pathological significance of the integrin α5β1 expression in endometrial adenocarcinoma|
|Authors:||Li, J;Lin, B;Zhang, X-R;Gao, T;Zhao, Z-H|
|subject:||Endometrial Adenocarcinoma;Immunohistochemistry;Integrin Α5β1|
|Description:||Purpose: To investigate the integrin α5β1 expression in endometrial adenocarcinoma and its relation with tumor differentiation, invasion, metastasis and prognosis. Methods: The integrin α5β1 expression was detected in 92 cases of endometrial adenocarcinoma by immunohistochemistry technique (PAP method). Results: The expression of integrin α5β1 in 77.1% cases with endometrial adenocarcinoma were weaker or loss. The positive rate of integrin α5β1 was lower in poorly differentiated carcinoma group than in well differentiated group (P < 0.05). The positive rate of integrin α5β1 was lower in lymph-node metastatic group than in nonmetastatic group (P < 0.05). The five-year survival rate of integrin α5β1 positive group was higher in integrin α5β1 positive group (78.4%) than that in negative group (19.2%, P< 0.05). Conclusions: The weak or loss expression of integrin α5β1 was correlated with differentiation and metastasis of endometrial adenocarcinoma. The expression of integrin α5β1 may have prognostic value.|
|Standard no:||Fudan University Journal of Medical Sciences, 2001, v. 28 n. 3, p. 251-253|
|Appears in Collections:||Department of Anatomy|
Files in This Item:
Click on the URI links for accessing contents.
Items in HannanDL are protected by copyright, with all rights reserved, unless otherwise indicated.